• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
TechPharmaceutical Industry
Europe

AstraZeneca to buy cell therapy biotech for up to $1 billion

By
Ashleigh Furlong
Ashleigh Furlong
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Ashleigh Furlong
Ashleigh Furlong
and
Bloomberg
Bloomberg
Down Arrow Button Icon
March 17, 2025, 7:50 AM ET
Pascal Soriot, chief executive officer of AstraZeneca.
Pascal Soriot, chief executive officer of AstraZeneca.Cole Burston/Bloomberg via Getty Images

AstraZeneca Plc, the UK drugmaker, agreed to buy the Belgian cell therapy developer EsoBiotec for as much as $1 billion to further boost its cancer capabilities. 

Recommended Video

AstraZeneca will pay $425 million upfront and may spend up to $575 million more in development and regulatory milestones, the companies said Monday. 

As Chief Executive Officer Pascal Soriot reaps the rewards of doubling down on the competitive market for cancer medicines with blockbusters like Tagrisso, Astra is targeting the next generation of potential treatments. 

EsoBiotec’s platform has the potential to transform cell therapy, according to Astra, by empowering the immune system to attack cancers. It uses targeted viruses to engineer immune cells directly within a person’s body and could allow treatment to be delivered in minutes rather than the current standard of several weeks. 

Astra shares were little changed in early London trading, rising less than 1%. The stock has gained almost 15% so far this year. 

Current CAR-T cell therapies require doctors to harvest cells from patients, engineer them in the laboratory and then re-infuse them into a patient. While these medicines can treat certain cancers, they are expensive and difficult to manufacture, prompting drugmakers to develop medicines that could engineer cells within the body. 

EsoBiotec in January announced the start of a trial testing its experimental therapy for multiple myeloma in collaboration with China’s Shenzhen Pregene Biopharma Co. The goal is to achieve cancer-free bone marrow without requiring chemotherapy to achieve lymphodepletion as needed in traditional CAR-T treatment.

Under the terms of the deal, EsoBiotec will become a subsidiary of Astra and maintain operations in Belgium. The transaction is expected to close in the second quarter. Prior to it, Esobiotec had only raised €22 million ($24 million).

In a separate cancer deal announced Monday, Astra agreed to license a plaform to make subcutaneous drug formulations from Alteogen Inc. It didn’t disclose financial details. 

Join us at the Fortune Workplace Innovation Summit May 19–20, 2026, in Atlanta. The next era of workplace innovation is here—and the old playbook is being rewritten. At this exclusive, high-energy event, the world’s most innovative leaders will convene to explore how AI, humanity, and strategy converge to redefine, again, the future of work. Register now.
About the Authors
By Ashleigh Furlong
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Tech

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Most Popular

placeholder alt text
Economy
Trump may have shot himself in the foot at the Fed, as Powell could stay on while Miran resigns from White House post
By Eleanor PringleFebruary 4, 2026
20 hours ago
placeholder alt text
Success
In 2026, many employers are ditching merit-based pay bumps in favor of ‘peanut butter raises’
By Emma BurleighFebruary 2, 2026
3 days ago
placeholder alt text
Investing
Tech stocks go into free fall as it dawns on traders that AI has the ability to cut revenues across the board
By Jim EdwardsFebruary 4, 2026
1 day ago
placeholder alt text
Cybersecurity
Top AI leaders are begging people not to use Moltbook, a social media platform for AI agents: It’s a ‘disaster waiting to happen’
By Eva RoytburgFebruary 2, 2026
3 days ago
placeholder alt text
North America
Gates Foundation doubles down on foreign aid as U.S. government largely withdraws
By Thalia Beaty and The Associated PressFebruary 3, 2026
2 days ago
placeholder alt text
Politics
Peter Thiel warns the Antichrist and apocalypse are linked to the ‘end of modernity’ currently happening—and cites Greta Thunberg as a driving example
By Nick LichtenbergFebruary 4, 2026
15 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Tech

Marc Rowan, chief executive officer of Apollo Global
NewslettersTerm Sheet
The 2026 private equity outlook appears hazy, says PitchBook
By Allie GarfinkleFebruary 5, 2026
10 minutes ago
InvestingMarkets
The ‘dumb money’ steps in as traders lose $1 trillion on the realization that AI will eat tech companies first
By Jim EdwardsFebruary 5, 2026
55 minutes ago
NewslettersFortune Tech
The sky’s the limit for Google capex
By Alexei OreskovicFebruary 5, 2026
1 hour ago
Lawhive's cofounders seated on a sofa.
Startups & VentureVenture Capital
Exclusive: Lawhive, a startup using AI to reimagine the general practice law firm, raises $60 million in new venture capital funding
By Jeremy KahnFebruary 5, 2026
4 hours ago
A man in a suit wearing glasses.
Big TechAlphabet
Alphabet plans to double capex spending to a possible $185 billion—but it’s keeping CEO Sundar Pichai up at night
By Amanda GerutFebruary 4, 2026
10 hours ago
electricity
EnvironmentElectricity
Over a million people are losing power during a freezing snowstorm while data centers nearby guzzle electricity
By Nikki Luke, Conor Harrison and The ConversationFebruary 4, 2026
14 hours ago